自体细胞因子诱导的杀伤细胞输注联合紫杉醇顺铂方案治疗晚期食管癌的疗效分析  

Analysis of the effect of injection in treatment of advanced esophageal cancer paclitaxel cisplatin regimen combined with autologous CIK cells

作　　者：朱惠平[1] 张全安[1] 

机构地区：[1]江苏省南京市第二医院,南京210003

出　　处：《中国肿瘤临床与康复》2014年第7期837-839,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨自体细胞因子诱导的杀伤细胞(CIK)输注联合紫杉醇顺铂方案治疗晚期食管癌的临床疗效。方法将76例晚期食管癌患者随机分为对照组和治疗组,每组38例。对照组患者采用常规紫杉醇顺铂联合方案治疗,治疗组患者采用自体CIK细胞输注与紫杉醇顺铂联合方案治疗。结果治疗组和对照组患者的肿瘤控制率分别为86.9%和63.2%,治疗组的治疗效果明显优于对照组(P<0.05)。治疗组的病情缓解时间以及治疗时间均较对照组显著缩短(P<0.05),治疗后存活时间明显长于对照组(P<0.05),临床死亡率明显低于对照组(P<0.05),治疗期间不良反应发生率明显低于对照组(P<0.05),患者对治疗方案的满意度明显高于对照组(P<0.05)。结论应用自体CIK细胞输注与紫杉醇顺铂联合方案治疗晚期食管癌患者的效果显著。Objective To explore clinical effect of autologous CIK cell infusion of paclitaxel com- bined with cisplatin in the treatment of advanced esophageal cancer. Methods 76 patients admitted to our hospital for patients with advanced esophageal cancer patients were randomly divided into treatment group and control group （38 cases respectively）. The control group received conventional paclitaxel combined with cisplatin and the treatment group autologous CIK cell infusion and paclitaxel plus cisplatin regimen. Results The curative effect of the treatment group was superior to that of the control group（P 〈 0.05） ;Remission time and implementation time of clinical treatment scheme were significantly shortened （ P 〈 0. 05 ） ; after treatment, survival time was significantly longer than that of the control group （ P 〈 0. 05 ） ; clinical mortality was significantly lower than that of the control group （P 〈 0. 05 ） ; The number of adverse reaction was less than the that of control group（P 〈 0.05） ;Degree of satisfaction with treatment was significantly higher than that of the control group （P 〈 0. 05 ）. Conclusion The paclitaxel cisplatin regimen combined with autolo- gnus CIK cells has significant effect on patients with advanced esophageal cancer.

关 键 词：细胞因子诱导的杀伤细胞 食管肿瘤 紫杉醇 顺铂 

分 类 号：R735.1[医药卫生—肿瘤]